ESCAPE试验:大血管闭塞卒中阿替普酶早期再通的深度解读
本分析基于ESCAPE试验中因大血管闭塞所致急性缺血性卒中患者,事后比较接受与未接受静脉阿替普酶者的早期再通率及其与90天良好结局的关联。未行血管内取栓者中,阿替普酶组早期再通率高于未用组,早期再通与良好结局相关,但多数患者仍未实现早期再灌注。
要点
- 未取栓患者中阿替普酶与更高早期再通率相关,校正风险比3.2。
- 早期再通者90天良好结局比例更高,校正风险比1.9。
- 阿替普酶组与未用组良好结局无显著差异,校正风险比1.0。
核心结论
- 早期再通被确认为未行血管内取栓患者良好结局的强预测因素,且静脉阿替普酶可提高早期再通率。
- 但多数患者(59.0%)未实现早期再灌注。
研究设计与样本
- ESCAPE试验的事后分析,纳入因大血管闭塞所致急性缺血性卒中患者。
- 分析147例未接受血管内取栓患者的早期再通与90天良好结局。
主要发现
- 未取栓患者中,未用阿替普酶者早期再通4/30(13.3%),使用阿替普酶者48/117(41.0%),校正风险比3.2(95% CI,1.2-8.1)。
- 良好结局:使用阿替普酶者34/116(29.3%)对比未用者10/29(34.5%),校正风险比1.0(95% CI,0.6-1.5)。
- 良好结局:有早期再通者20/52(38.5%)对比无早期再通者24/93(25.8%),校正风险比1.9(95% CI,1.2-2.9)。
临床怎么用
- 对大血管闭塞急性缺血性卒中患者,静脉阿替普酶可提高早期再通机会。
- 早期再通与90天良好结局相关,支持重视再通评估与实现。
局限性
- 为ESCAPE试验的事后分析,仅纳入未接受血管内取栓的147例患者。
- 早期再通与良好结局的关联为观察性比较,需结合试验整体设计解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Quantitating the effect of intravenous alteplase on the technical outcome of early recanalization of large vessel occlusions aids understanding. We report the prevalence of early recanalization in patients with stroke because of large vessel occlusion treated with and without intravenous alteplase and endovascular thrombectomy, and its association with clinical outcome. METHODS: Patients with acute ischemic stroke with large vessel occlusion from the ESCAPE trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times Trial) were included in this post hoc analysis. Outcomes of interest were the prevalence of early recanalization (1) and good outcome (2), defined as modified Rankin Scale score of 0 to 2 at 90 days. RESULTS: Among 147 patients who did not receive endovascular thrombectomy, early recanalization occurred in 4/30 (13.3%) patients without and 48/117 (41.0%) patients with intravenous alteplase (adjusted risk ratios, 3.2 [95% CI, 1.2-8.1]). Good outcome was achieved by 34/116 (29.3%) of patients who received intravenous alteplase versus 10/29 (34.5%) who did not receive alteplase (adjusted risk ratios, 1.0 [95% CI, 0.6-1.5) and by 20/52 (38.5%) patients with versus 24/93 (25.8%) without early recanalization (adjusted risk ratios, 1.9 [95% CI, 1.2-2.9]). CONCLUSIONS: Early recanalization was confirmed as a strong predictor of good outcome in patients who did not undergo endovascular thrombectomy and was improved with intravenous alteplase, yet a majority of patients (59.0%) did not achieve early reperfusion. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01778335.
引用
- Ospel JM, Singh N, Almekhlafi MA, et al. Early Recanalization With Alteplase in Stroke Because of Large Vessel Occlusion in the ESCAPE Trial. Stroke. 2020. PMID: 33213288. doi:10.1161/STROKEAHA.120.031591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。